Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome

ObjectiveOn the basis of the known diabetes risk in polycystic ovary syndrome (PCOS), recent guidelines of the Endocrine Society recommend the use of an oral glucose tolerance test (OGTT) to screen for impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) in all women with PCOS. However, given the high prevalence of PCOS, OGTT would have a high cost–benefit ratio. In this study, we identified, through a receiver operating characteristic analysis, simple predictive markers of the composite endpoint (impaired fasting glucose (IFG) or IGT or IFG+IGT or T2DM) in women with PCOS according to the Rotterdam criteria.DesignWe conducted a cross-sectional study of 241 women with PCOS in a university hospital setting.MethodsClinical, anthropometric, and metabolic (including OGTT) parameters were evaluated. The homeostasis model assessment of insulin resistance (HOMA2-IR), the Matsuda index of insulin sensitivity, and the oral dispositional index and visceral adiposity index (VAI) were determined.ResultsOut of 241 women included in this study, 28 (11.6%) had an IFG, 13 (5.4%) had IGT, four (1.7%) had IFG+IGT, and four (1.7%) had T2DM. Among the anthropometric variables examined, the VAI had a significantly higher C-statistic compared with BMI (0.760 (95% CI: 0.70–0.81) vs 0.613 (95% CI: 0.54–0.67);P=0.014) and waist circumference (0.760 (95% CI: 0.70–0.81) vs 0.619 (95% CI: 0.55–0.68);P=0.028). Among all the hormonal and metabolic serum variables examined, DHEAS showed the highest C-statistic (0.720 (95% CI: 0.65–0.77);P<0.001).ConclusionsIn addition to fasting glucose, the VAI and DHEAS may be considered useful tools for prescreening in all women with PCOS without the classical risk factors for diabetes.

Download Full-text

The Role of Visceral Adiposity Index as Predictor of Metabolic Syndrome in Obese and Nonobese Women with Polycystic Ovary Syndrome

Metabolic Syndrome and Related Disorders ◽

10.1089/met.2020.0045 ◽

2020 ◽

Author(s):

Sebastião Freitas de Medeiros ◽

Matheus Antônio Souto de Medeiros ◽

Bruna Barcelo Barbosa ◽

Márcia Marly Winck Yamamoto

Keyword(s):

Metabolic Syndrome ◽

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Visceral Adiposity ◽

Visceral Adiposity Index ◽

Ovary Syndrome ◽

Adiposity Index

Download Full-text

Visceral adiposity index correlation with Rotterdam criteria in patients with polycystic ovary syndrome

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20162623 ◽

2016 ◽

pp. 2553-2560

Author(s):

Mohamed Aboelnaga ◽

H. Elshahawy

Keyword(s):

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Visceral Adiposity ◽

Visceral Adiposity Index ◽

Ovary Syndrome ◽

Adiposity Index ◽

Rotterdam Criteria

Download Full-text

Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters

Journal of Endocrinological Investigation ◽

10.1007/s40618-016-0582-x ◽

2016 ◽

Vol 40 (5) ◽

pp. 487-497 ◽

Cited By ~ 20

Author(s):

U. Durmus ◽

C. Duran ◽

S. Ecirli

Keyword(s):

Polycystic Ovary Syndrome ◽

Polycystic Ovary ◽

Visceral Adiposity ◽

Visceral Adiposity Index ◽

Obese Patients ◽

Ovary Syndrome ◽

Adiposity Index ◽

Inflammatory Parameters

Download Full-text

Adiposity Indexes as Phenotype-Specific Markers of Preclinical Metabolic Alterations and Cardiovascular Risk in Polycystic Ovary Syndrome: A Cross-Sectional Study

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0042-119524 ◽

2017 ◽

Vol 125 (05) ◽

pp. 307-315 ◽

Cited By ~ 5

Author(s):

Fernanda Mario ◽

Scheila Graff ◽

Poli Spritzer

Keyword(s):

Cardiovascular Risk ◽

Polycystic Ovary Syndrome ◽

Lipid Accumulation ◽

Polycystic Ovary ◽

Visceral Adiposity ◽

Visceral Adiposity Index ◽

Lipid Accumulation Product ◽

Ovary Syndrome ◽

Metabolic Alterations ◽

Adiposity Index

AbstractPolycystic ovary syndrome (PCOS) is a common condition in women of reproductive age. 2 PCOS phenotypes (classic and ovulatory) are currently recognized as the most prevalent, with important differences in terms of cardiometabolic features. We studied the performance of different adiposity indexes to predict preclinical metabolic alterations and cardiovascular risk in 234 women with PCOS (173 with classic and 61 with ovulatory PCOS) and 129 controls. Performance of waist circumference, waist-to-height ratio, conicity index, lipid accumulation product, and visceral adiposity index was assessed based on HOMA-IR ≥ 3.8 as reference standard for screening preclinical metabolic alterations and cardiovascular risk factors in each group. Lipid accumulation product had the best accuracy for classic PCOS, and visceral adiposity index had the best accuracy for ovulatory PCOS. By applying the cutoff point of lipid accumulation product<34, we identified a subgroup of patients without cardiometabolic alterations (P<0.05) in the group with classic PCOS, a population at higher risk for hypertension, dyslipidemia, and impaired glucose tolerance. In ovulatory PCOS, visceral adiposity index ≥ 1.32 was capable of detecting women with significantly higher blood pressure and less favorable glycemic and lipid variables as compared to ovulatory PCOS with lower visceral adiposity index (P<0.05). These results suggest LAP ≥ 34 as the best marker for classic PCOS, and VAI ≥ 1.32 for ovulatory PCOS women. Both indexes can be easily calculated with measures obtained in routine clinical practice and may be useful to detect cardiometabolic risk and secure early interventions.

Download Full-text